10-Q: Helius Medical Technologies Reports Q2 2024 Results, Navigates Financial Challenges

Helius Medical Technologies reported a net loss of $1.6 million for the second quarter of 2024, while making progress on commercialization and reimbursement efforts for its PoNS device.

Summary

• Helius Medical Technologies reported a net loss of $1.6 million for both the three and six months ended June 30, 2024.
• The company's revenue for the three months ended June 30, 2024 was $182 thousand, a decrease from $256 thousand in the same period last year.
• For the six months ended June 30, 2024, revenue was $317 thousand, down from $367 thousand in the prior year period.
• The company's cash and cash equivalents stood at $6.4 million as of June 30, 2024.
• Helius completed a public offering in May 2024, raising approximately $5.5 million in net proceeds.
• The company is transitioning manufacturing of its PoNS device to Minnetronix, Inc., expected to be completed in the third quarter of 2024.
• Helius is pursuing commercial insurance coverage and Medicare reimbursement for PoNS, with CMS expected to publish final reimbursement amounts in late August or early September 2024.
• The company is conducting clinical trials for stroke and risk of fall programs, with enrollment expected to be completed by the end of 2024 and a submission to the FDA targeted for mid-to-late 2025.
• The company has received a notice from Nasdaq for not meeting the minimum bid price requirement and has until February 5, 2025 to regain compliance.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in commercialization and reimbursement efforts, it faces significant financial challenges, including ongoing losses, a low cash position, and a Nasdaq delisting notice. The going concern uncertainty and the need for additional capital raise further contribute to a negative sentiment.

Positives

• Helius successfully raised $5.5 million through a public offering in May 2024.
• The company is actively pursuing reimbursement for its PoNS device through commercial insurance and Medicare.
• Helius has partnered with Lovell Government Services to expand access to the PoNS device within federal healthcare systems.
• The company is progressing with clinical trials for stroke and risk of fall programs, which could expand the market for PoNS.
• Helius has established sales representative agreements to sell PoNS devices to Veterans Affairs facilities in the U.S.

Negatives

• The company reported a net loss of $1.6 million for the three months ended June 30, 2024, and a net loss of $4.1 million for the six months ended June 30, 2024.
• Revenue decreased compared to the same periods in the prior year.
• Helius received a notice from Nasdaq for not meeting the minimum bid price requirement, which could lead to delisting.
• The company has an accumulated deficit of $164.1 million as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing operating losses and cash outflows.
• Helius is dependent on successful commercialization of PoNS Therapy in the U.S. to achieve profitability.
• The company faces risks related to global economic conditions, including supply chain disruptions, labor shortages, and increased inflation.
• There is a risk of delays or disruptions in the manufacturing process during the transition to a new contract manufacturer.
• The company's stock may be delisted from Nasdaq if it does not regain compliance with the minimum bid price requirement.
• The company may not be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the company.

Future Outlook

The company expects to continue to incur operating losses and net cash outflows until it generates sufficient revenue to support its cost structure. Helius intends to use its available capital to expand U.S. commercialization efforts, fund manufacturing, conduct clinical trials, and for working capital. The company believes its existing capital resources and the $5.5 million net proceeds from the May 2024 offering will be sufficient to fund operations into 2025, but additional funding will be required thereafter.

Management Comments

• The company is actively pursuing commercial insurance coverage and Medicare reimbursement for PoNS.
• Helius is focused on expanding access to the PoNS device through partnerships and sales representative agreements.
• The company is committed to advancing clinical trials for stroke and risk of fall programs.

Industry Context

The neurotechnology industry is focused on developing innovative solutions for neurological conditions. Helius's PoNS device is positioned within this space, targeting gait and balance deficits. The company's efforts to secure reimbursement and expand its market reach are consistent with industry trends, but it faces competition and regulatory hurdles.

Comparison to Industry Standards

• Helius's revenue of $182 thousand for the three months ended June 30, 2024, is low compared to established medical device companies, such as Medtronic or Stryker, which report billions in quarterly revenue.
• The company's net loss of $1.6 million for the quarter is typical for early-stage medical device companies that are still in the commercialization phase, but it is higher than some peers that have achieved profitability.
• The company's cash position of $6.4 million is relatively low compared to larger companies in the medical device sector, which often have hundreds of millions or billions in cash reserves.
• The company's reliance on self-pay and VA patients for initial sales is a common strategy for companies launching new medical devices, but it is not sustainable in the long term without broader reimbursement coverage.
• The company's efforts to secure Medicare reimbursement are critical for long-term success, as Medicare is a major payer in the U.S. healthcare system. Companies like Insulet, which manufactures the Omnipod insulin pump, have demonstrated the importance of securing Medicare coverage for medical devices.
• The company's clinical trials for stroke and risk of fall programs are consistent with industry standards for expanding the indications for medical devices. Companies like Boston Scientific have a history of conducting clinical trials to support new indications for their products.

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential capital raises and the risk of delisting from Nasdaq.
• Employees may be impacted by potential cost-cutting measures if the company is unable to secure additional funding.
• Customers may experience delays or disruptions in the availability of the PoNS device during the manufacturing transition.
• Suppliers may be affected by changes in the company's manufacturing and supply chain.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will continue to pursue commercial insurance coverage and Medicare reimbursement for PoNS.
• Helius will continue to transition manufacturing of its PoNS device to Minnetronix, Inc.
• The company will continue to conduct clinical trials for stroke and risk of fall programs.
• Helius will monitor the closing bid price of its Common Stock and consider options to regain compliance with Nasdaq's minimum bid price requirement.
• The company will seek additional funding through the sale of equity or debt financing to continue to fund its operations after 2025.

Key Dates

Keywords

PoNS, neuromodulation, gait deficit, balance deficit, multiple sclerosis, stroke, traumatic brain injury, Medicare, reimbursement, clinical trials, medical device, FDA, Nasdaq, public offering